Yarrow Bioscience (YARW) Raw Materials (2021)
Yarrow Bioscience's (YARW) quarterly Raw Materials came in at $3.3 million in Q4 2021.
Analysis
Yarrow Bioscience (YARW) Raw Materials (2021) Analysis & Trends
Yarrow Bioscience (YARW) has reported Raw Materials for 1 consecutive years, with $3.3 million the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Raw Materials changed N/A year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2021 stood at $3.3 million (changed N/A YoY), and the FY2021 full-year result was $3.3 million, changed N/A from the prior year.
- Raw Materials held at $3.3 million in Q4 2021 per YARW's latest filing.
- Across five years, Raw Materials topped out at $3.3 million in Q4 2021 and bottomed at $3.3 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.17 Bn | 622.42 Bn | 17.26 Bn |
| 2 | AbbVie | 446.97 Bn | 440.40 Bn | 12.70 Bn |
| 3 | Merck | 359.56 Bn | 352.42 Bn | 12.21 Bn |
| 4 | Novartis Ag | 269.46 Bn | 261.77 Bn | 11.24 Bn |
| 5 | Pfizer | 156.92 Bn | 145.22 Bn | 10.94 Bn |
| 6 | Sanofi | 52.38 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.58 Bn | 43.58 Bn | - |
| 8 | Incyte | 25.22 Bn | 20.68 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.29 Bn | 18.63 Bn | 683.80 Mn |
| 10 | Yarrow Bioscience | 25.73 Mn | 2.80 Mn | - |